Skip to Content

Francois-Xavier Claret, Ph.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Systems Biology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Associate Professor, Graduate School of Biomedical Sciences (GSBS), University of Texas Medical School (UTMS) and Health Science Center (HSC). Program affiliation in Cancer Biology, Houston, TX
Associate Professor, Graduate School of Biomedical Sciences (GSBS), University of Texas Medical School (UTMS) and Health Science Center (HSC), Houston, TX, U.S. Program affiliation in Experimental Therapeutics Academic Program, Houston, TX

Research Interests

  • Translational oncology

  • Cell signaling

  • Cell cycle control

  •    Animal models of cancer
  •    Drug discovery/small molecules


My research focuses on understanding how cells  receive, read and relay molecular communication signals, and how disruptions  in these processes lead to tumor formation and cancer metastasis. The long-term goal of my research is to identify novel targets that can be translated into new therapeutic approaches for cancer patients. We are interested in delineating  the molecular mechanisms that enable tumor cells to respond to and survive  genotoxic stress. We are  approaching these questions by analyzing the mitogen-activated protein kinase (MAPK) pathway, as well as cell cycle control inhibitor and the tumor suppressor p27. Our efforts to  translate our new understanding of molecular mechanisms to the clinic will produce more  specific therapies for treating cancer patients than current chemotherapeutic  drugs. These new strategies should block some of the signaling pathways that we  know are inappropriately activated in many cancers.

·    Project 1:  MAPK Signaling in Chemotherapy  Responses: Signals for Suicide and Resistance

   We are analyzing how the MAPK signaling pathways, which are initiated at the cell surface,  control the expression of genes in the nucleus and cellular events such as cell  differentiation, cell proliferation and cell death. We aim to  identify the  stress-induced signaling  pathways as a mechanism underlying the resistance to cancer chemotherapeutic  agents (e.g. cisplatin) in breast and ovarian cancers.

·   Project 2: Positive and Negative Regulatorsof Cell Cycle Progression: Potential and Novel Therapeutic Targets for Human  Cancers. Cellular proliferation is controlled by cyclin-dependent kinases (Cdks) whose activities are absolutely required for cell cycle progression. Cdks are regulated positively by cyclins and negatively by Cdk inhibitors. We are studying c-Jun  activation domain binding protein (JAB1); which  we initially identified as a pivotal co-activator of c-Jun and promotes cellular  proliferation by mediating the degradation of the cell cycle inhibitor p27Kip1.  JAB1 is overexpressed in breast cancer and is a central player in cell  cycle progression because it negatively regulates the cell cycle inhibitor p27.  Thus, JAB1 contributes to the loss of p27 tumor suppressor function that is  seen in over 50% of aggressive breast cancer tumors and is related to poor  clinical outcomes. Our current work aims at  unraveling the biological function of JAB1 with biochemical and genetic tools. We are studying  the role of JAB1 in cell cycle progression, DNA-damage, DNA-repair and tumorigenesis.

·     Project 3: Modeling Cancer  in  Mice to Examine Therapeutic Targets. Targeting  JAB1 may offer a therapeutic approach to restoring the tumor suppressor function of  p27kip1 and killing tumor cells. Therefore, we have developed a gene therapy approach to silence endogenous JAB1 levels in  fluorescent-labeled breast tumor cells with retrovirus driven in short-hairpin  RNA in vivo tumor models from  xenograft/orthotopic implantation models. Tumor  growths are being monitored through noninvasive in vivo fluorescence  imaging (real-time whole-body imaging). We are also establishing s transgenic mouse model to investigate whether JAB1  overexpression contributes to mammary tumorigenesis. Furthermore, we are using advanced gene  targeting methods to investigate whether JAB1 overexpression contributes  to lymphoma development and shorter mouse survival.  For this purpose we are using the transgenic Emu-myc  model of B-cell lymphoma, to generate  double-transgenic Emu-myc+/Jab1+ mice.

·     Project 4: Developing New  Approaches for Therapeutic Resistance in HER2-positive Breast Cancer.Trastuzumab (Herceptin), a humanized monoclonal antibody to the transmembrane HER2/neu (also known as ErbB-2) protein,  is the most effective targeted therapy for patients with metastatic breast  cancers that overexpress HER2. However, pre-existing or acquired trastuzumab  resistance is a major obstacle in the clinical management of HER2-positive breast cancer. Studies have suggested an interesting  association between the mechanism of resistance to trastuzumab and p27. Using pre-clinical studies and targeting key signaling pathways we are  developing novel therapeutic strategies to sensitize  tumor cells to trastuzumab treatment  (e.g. combined therapies).

Office Address

The University of Texas MD Anderson Cancer Center
Division of Cancer Medicine, Department of Systems Biology
7435 Fannin Street
Unit Number: 950
Houston, TX 77054
Room Number: 2SCR3.2026
Phone: 713-563-4204

Education & Training

Degree-Granting Education

1993 University of Lausanne, Lausanne, Switzerland, Ph.D., Molecular Biology
1987 University of Lausanne, Lausanne, Switzerland, Predoctoral, Biology Diploma, Biology
1986 University Paul Sabatier, Toulouse, France, Maitrise de Biologie Cellulaire, Cellular Biology
1985 University Paul Sabatier, Toulouse, France, License de Biochimie, Biochemistry
1984 University Paul Sabatier, Toulouse, France, License de Biologie Cellulaire et Physiologie, Cellular Biology
1983 University Paul Sabatier, Toulouse, France, DEUG-B Sciences, Biology

Postgraduate Training

1993-1997 Research Fellowship, Cell Signaling, University of California San Diego (UCSD), School of Medicine, La Jolla, CA, (Dr. Michael Karin)


Institutional Committee Activities

Member, Admission Committee, Graduate School of Biomedical Sciences (GSBS), 2011-present
Member, Executive Committee of the Experimental Therapeutics Academic Program (ETAP), 2010-present
Member, Institutional Research Grants Program (Basic Science), 2009-present
Member, TRIUMPH Postdoctoral Program in translational research, 2007-present
Member, Faculty Advisory Board, Altana Pharma Award, 2002-2007
Member, Faculty Advisory Board, Odyssey Scholars and Fellows Program, 1999-2007

Honors and Awards

2012 Individual Investigator Award, Cancer Prevention & Research Institute of Texas
2008 Best Boss Award Nominee, MD Anderson Cancer Center
2003 The Leading BioScientists of the Next Decade, ROCHE
1995 Advanced Post-doctoral Research Fellowship, Swiss National Science Foundation
1993 Long term fellowship, Human Frontiers Science Program Fellowship

Selected Publications

Peer-Reviewed Original Research Articles

1. Wang S, Zhang R, *Claret FX, *Yang H (*) Co-corresponding authors. Involvement of microRNA-24 and DNA Methylation in Resistance of Nasopharyngeal Carcinoma to Ionizing Radiation. Mol Cancer Ther, 2014. PMID: 25319395.
2. Vu TT, Sliwkowski MX, Claret FX. Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochimica et Biophysica Acta - Reviews on Cancer 1846(2):353-365, 2014. PMID: 25065528.
3. Astaves V, Lekakis L, Drakos I, Leventaki V, Jones D, Feretzaki M, Liakou C, Korapati A, Horie R, Panayiotidis P, Gorgoulis V, Patsouris E, Medeiros JL, Claret FX, Rassidakis G. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma. Br J Haematol. 2014. PMID: 25145835.
4. Zhou F, Meng S, Song H, Claret FX.. Dickkopf-1 is a key regulator of myeloma bone disease: Opportunities and challenges for therapeutic intervention. Blood Reviews 27(6):261–267, 9/2013. PMID: 24054128.
5. Zhou F, Shen Q, Claret FX.. Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. Journal of Leukocyte Biology 94(3):423-9, 9/2013. PMID: 23715741.
6. Pan Y, Wang M, Bu X, Zuo Y, Wang S, Wang D, Liu Q, Xu T, Wang C, Claret FX, Yang H. Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma. BMC cancer 13(1):323, 7/2013. PMID: 23815987.
7. Pan Y, Zhang Q, Atsaves V, Yang H, Claret FX. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene 32(22):2756-66, 5/2013. PMCID: PMC3566273.
8. Echalier A*, Pan Y*, Birol M, Tavernier N, Pintard L, Hoh F, Ebel C, Galophe N, Claret FX, Dumas C. (*) Equal contribution. Insights into the regulation of the human Cop9 signalosome catalytic subunit, CSN5/Jab1. Proceedings of the National Academy of Sciences U S A (PNAS) 110(4):1273-8, 1/2013. PMID: 23288897.
9. Pan Y, Zhou F, Zhang R, Claret FX. Stat3 inhibitor Stattic exhibits potent antitumor activity and induces chemo- and radio-sensitivity in nasopharyngeal carcinoma. PLOS ONE 8(1):e54565,, January 29, 2013. PMCID: PMCPMC3558509.
10. Vu T and Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Frontiers in Cancer Molecular Targets and Therapeutics. 2(62), 6/2012. PMCID: PMC3376449.
11. Pan Y, Zhang Q, Tian L, Wang X, Fan X, Zhang H, Claret FX, Yang H. Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma. Cancer Research 72(7):1890-1900, 4/2012. PMCID: PMC3460549.
12. Zhang Q, Claret FX. Phosphatases: the new brakes for cancer development? Enzyme Research 2012(659649), 2012. e-Pub 10/2011. PMCID: PMC3206369.
13. Shackleford TJ, Zhang Q, Tian L, Vu TT, Korapati AL, Baumgartner A, Le XF, Liao WS, Claret FX.. STAT3 and CCAAT/Enhancer Binding Protein beta (C/EBP-β) regulate Jab1/CSN5 expression in mammary carcinoma cells. Breast Cancer Research 13(3):R65, 6/2011. PMCID: PMC3218954.
14. Drakos E, Rassidakis G, Schlette E, Li J, Singh RJ, Vega F, Claret FX, Ford J, Medeiros LJ.. Activation of p53 Pathway by MDM2 Inhibitor Nutlin-3a Overcomes BCL2 Overexpression in a Preclinical Model of Diffuse Large B-cell Lymphoma Associated with t(14;18)(q32;q21). Leukemia (Nature Publishing Group) 5(25):856-867, 2011. PMCID: PMC3094765.
15. Drakos E, Leventaki V, Atsaves V, Schlette EJ, Lin P, Vega F, Claret FX, Medeiros JL, Rassidakis GZ.. Expression of Serine 194-phosphorylated FADD strongly correlates with proliferation in B-cell Non-Hodgkin lymphomas. Human Pathology 42(8):1117-24, 2011. PMID: 21315423.
16. Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.. The Role of p27Kip1 in Dasatinib-Enhanced Paclitaxel Cytotoxicity in Human Ovarian Cancer Cells. Journal of the National Cancer Institute (JNCI) 103(18):1403-22, 2011. PMCID: PMC3176777.
17. Tian L, Peng G, Parant JM, Leventaki V, Drakos I, Zhang Q, Parker-Thornburg J, Shackleford T, Dai H, Lin, S-Y. Lozano G, Rassidakis, GZ, Claret FX.. Essential Roles of Jab1 in Cell Survival, Spontaneous DNA Damage, and DNA Repair. Oncogene (Nature Publishing Group) 29(46):6125-6137, 2010. PMCID: PMC3495558.
18. Shackleford T, Claret FX. JAB1: a new player in cell cycle control and cancer. Cell Division 5(1):1-14, 2010. PMCID: PMC2976740.
19. Vivas-Mejia P, Benito JM, Fernandez A, Han HD, Mangala L, Rodriguez-Aguayo C, Chavez-Reyes A, Lin YG, Carey MS, Nick AM, Stone RL, Kim HS, Claret FX, Bornmann W, Hennessy BT, Sanguino A, Peng Z, Sood AK, Lopez-Berestein G. JNK-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer. Clinical Cancer Research 1(16):184-94, 2010. PMID: 20028751.
20. Shin S, Asano T, Yao Y, Krishnan K, Korc M, Sabapathy K, Menter DG, Claret FX, Abbruzzese JL and Reddy SA.. Activator Protein-1 has an essential role in pancreatic cancer cells and is regulated by a novel AKT-mediated mechanism. Molecular Cancer Research 7(5):745-54, 2009. PMID: 19435822.
21. Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, Gallick GE, Mills GB, Wiener JR. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. International Journal of Oncology 31(2):441-9, 2007. PMID: 17611702.
22. Leventaki V, Drakos E, Medeiros LJ, Lim MS, Elenitoba-Johnson KS, Claret FX and Rassidakis GZ.. NPM-ALK oncogenic kinase promotes cell cycle progression through activation of JNK/c-Jun signalling in anaplastic large cell lymphoma. Blood 110(5):6589-89, 2007. PMID: 17416736.
23. Vega F, Medeiros JF, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Research 66(13):6589-97, 2006. PMID: 16818631.
24. Kim HJ, Chakravarti N, Oridate N, Choe C, Claret FX, Lotan R. N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene 25(19):2785-94, 2006. PMCID: PMC1458365.
25. Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao P, Ho L, Evans DB, Claret FX. Potential Role of Jun Activation Domain-Binding Protein 1 as a Negative Regulator of p27kip1 in Pancreatic Adenocarcinoma. Cancer Research 66(17):8581-9, 2006. PMCID: PMC1780177.
26. Zhang Q, Tian L, Mansouri A, Korapati AL, Johnson TJ, Claret FX. Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells. FEBS Letters 579(18):3932-40, 2005. PMCID: PMC1366489.
27. Rassidakis GZ, Feretzaki M, Atwell C, Grammatikakis I, Lin Q, Lai R, Claret FX, Medeiros LJ, Amin HM. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood 105(2):827-9, 2005. PMCID: PMC1382060.
28. Rassidakis GZ, Thomaides A, Atwell C, Ford R, Jones D, Claret FX, Medeiros LJ. JunB expression is a common feature of CD30+ lymphomas and lymphomatoid papulosis. Modern Pathology 18(10):1365-70, 2005. PMCID: PMC1382062.
29. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. Journal of Biological Chemistry 279(10):9653-61, 2004. PMID: 14670967.
30. Mansouri A, Zhang Q, Ridgway LD, Tian L, Claret FX. Cisplatin resistance in an ovarian carcinoma is associated with a defect in programmed cell death control through XIAP regulation. Oncology Research 13(6-10):399-404, 2003. PMID: 12725530.
31. Rassidakis GZ, Claret FX, Lai R, Zhang Q, Sarris AH, McDonnell TJ, Medeiros LJ. Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. Clinical Cancer Research 9(3):1121-8, 2003. PMID: 12631617.
32. Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clinical Cancer Research 9(15):5652-9, 2003. PMID: 14654548.
33. Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX. Jun activation domain-binding protein 1 (JAB1) expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1). Cancer Research 63(11):2977-81, 2003. PMID: 12782606.
34. Pyle ME, Korbonits M, Gueorguiev M, Jordan S, Kola B, Morris DG, Meinhardt A, Powell MP, Claret FX, Zhang Q, Metz C, Bucala R, Grossman AB. Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. Journal of Endocrinology 176(1):103-10, 2003. PMID: 12525254.
35. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. Journal of Biological Chemistry 278(21):19245-56, 2003. PMID: 12637505.
36. Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC, Jr. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. Journal of Biological Chemistry 278(26):23441-50, 2003. e-Pub 4/2003. PMID: 12700233.
37. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX, Grossman AB. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. Journal of Clinical Endocrinology & Metabolism 87(6):2635-43, 2002. PMID: 12050228.
38. Aytac U, Claret FX, Ho L, Sato K, Ohnuma K, Mills GB, Cabanillas F, Morimoto C, Dang NH. Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. Cancer Research 61(19):7204-10, 10/2001. PMID: 11585756.
39. Deng L, Lin-Lee YC, Claret FX, Kuo MT. 2-acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. Journal of Biological Chemistry 276(1):413-20, 2001. PMID: 11020383.
40. Lee HY, Sueoka N, Hong WK, Mangelsdorf DJ, Claret FX, Kurie JM. All-trans-retinoic acid inhibits Jun N-terminal kinase by increasing dual-specificity phosphatase activity. Molecular and Cellular Biology 19(3):1973-80, 1999. PMCID: PMC83990.
41. Le-Niculescu H, Bonfoco E, Kasuya Y, Claret FX, Green DR, Karin M. Withdrawal of survival factors results in activation of the JNK pathway in neuronal cells leading to Fas ligand induction and cell death. Molecular and Cellular Biology 19(1):751-63, 1999. PMCID: PMC83932.
42. *Herdegen T, *Claret FX, Kallunki T, Martin-Villalba A, Winter C, Hunter T, Karin M (*) Equal contribution. Lasting N-terminal phosphorylation of c-Jun and activation of c-Jun N-terminal kinases after neuronal injury. Journal of Neuroscience 18(14):5124-35, 1998. PMID: 9651196.
43. Lee HY, Dawson MI, Claret FX, Chen JD, Walsh GL, Hong WK, Kurie JM. Evidence of a retinoid signaling alteration involving the activator protein 1 complex in tumorigenic human bronchial epithelial cells and non-small cell lung cancer cells. Cell Growth & Differentiation 8(3):283-91, 1997. PMID: 9056670.
44. Claret FX, Antakly T, Karin M, Saatcioglu F. A shift in the ligand responsiveness of thyroid hormone receptor alpha induced by heterodimerization with retinoid X receptor alpha. Molecular and Cellular Biologyl 16(1):219-27, 1996. PMCID: PMC230995.
45. Claret FX, Hibi M, Dhut S, Toda T, Karin M.. Jun activation-domain binding proteins (JAB1): a new group of conserved coactivators that increase the specificity of AP-1 factors. Nature 383(6599):453-457, 1996. PMID: 8837781.
46. Lin A, Minden A, Martinetto H, Claret FX, Lange-Carter C, Mercurio F, Johnson GL, Karin M. Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 268(5208):286-90, 1995. PMID: 7716521.
47. Cavigelli M, Dolfi F, Claret FX, Karin M. Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO Journal 14(23):5957-64, 1995. PMCID: PMC394715.
48. Minden A, Lin A, Claret FX, Abo A, Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 81(7):1147-57, 1995. PMID: 7600582.
49. Saatcioglu F, Claret FX, Karin M. Negative transcriptional regulation by nuclear receptors. Seminars in Cancer Biology 5(5):347-59, 10/1994. PMID: 7849263.
50. Arias J, Alberts AS, Brindle P, Claret FX, Smeal T, Karin M, Feramisco J, Montminy M. Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. Nature 370(6486):226-9, 1994. PMID: 8028671.
51. Claret FX, Chapel S, Garces J, Tsai-Pflugfelder M, Bertholet C, Shapiro DJ, Wittek R, Wahli W. Two functional forms of the Xenopus laevis estrogen receptor translated from a single mRNA species. Journal of Biological Chemistry 269(19):14047-55, 1994. PMID: 8188685.
52. Schild C, Claret FX, Wahli W, Wolffe AP. A nucleosome-dependent static loop potentiates estrogen-regulated transcription from the Xenopus vitellogenin B1 promoter in vitro. EMBO Journal 12(2):423-33, 1993. PMCID: PMC413225.
53. *Corthesy B, *Claret FX, Wahli W (*) Equal contribution. Estrogen receptor level determines sex-specific in vitro transcription from the Xenopus vitellogenin promoter. Proceedings of the National Academy of Sciences U S A (PNAS) 87(20):7878-82, 1990. PMCID: PMC54854.
54. Corthesy B, Cardinaux JR, Claret FX, Wahli W. A nuclear factor I-like activity and a liver-specific repressor govern estrogen-regulated in vitro transcription from the Xenopus laevis vitellogenin B1 promoter. Molecular and Cellular Biology 9(12):5548-62, 1989. PMCID: PMC363725.
55. Heggler-Bordier B, Claret FX, Wahli W. Immuno-electron microscopic identification of human estrogen receptor-DNA complexes at the estrogen-responsive element and in the first intron of a Xenopus vitellogenin gene. Journal of Molecular Biology 204(1):217-20, 1988. PMID: 3216393.

Invited Articles

1. Pan Y, Yang H, Claret FX. Emerging Roles of Jab1/Csn5 in DNA Damage Response, DNA Repair and Cancer. Cancer Biol Ther 15(3):256-62, 3/1/2014. e-Pub 2/4/2014. PMCID: PMC3974825.
2. Vu TT, Sliwkowski MX, Claret FX. Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1846(2):353-365, 2014. PMID: 25065528.
3. Zhou F, Meng S, Claret FX. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention. Blood Reviews, 9/2013. PMID: 24054128.
4. Zhou F, Shen Q, Claret FX.. Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. Journal of Leukocyte Biology 94(3):423-9, 9/2013. PMID: 23715741.
5. Claret FX, Shackleford T. JNK in cancer development. Chapter: Encyclopedia of Cancer Therapeutic Targets; Georgetown Lombardi; Springer Science & Business Media Publishing, Ed. John L. Marshall. New York, NY, USA, 2013.
6. Vu T, Claret FX. Trastuzumab: updated mechanisms of action and resistance in breast cancer. Frontiers in Cancer Molecular Targets and Therapeutics. 2(62), 6/2012. PMCID: PMC3376449.
7. Pan Y, Claret FX. Targeting Jab1/CSN5 in nasopharyngeal carcinoma. Cancer Letters 2(326):155-60, 2012. PMCID: PMC3474602.
8. Zhang Q, Claret FX.. Phosphatases: The New Brakes for Cancer Development? Enzyme Research 2012(659649). e-Pub 2011. PMCID: PMC3206369.
9. Mansouri, A, Ridgway, LD Claret, F-X.. Activation of the JNK/SAPK and p38 mitogen-activated protein kinase signaling pathways sensitize tumor cells to cisplatin-induced apoptosis. TheScientificWorldJOURNAL 1 (1 Suppl)(3):35-36, 2001. PMID: 10.1100.
10. Saatcioglu F, Claret FX, Karin M.. Negative transcriptional regulation by nuclear receptors. Seminars in Cancer Biology 5:347-359, 1994. PMID: 7849263.

Grant & Contract Support

Funding Source: Sister Institution Network Fund (SINF) - Global Academic Program (GAP)
Role: Principal Investigator
Duration: 12/2/2013 - 12/1/2015
Title: Novel Strategy for Treatment of HER2-Positive Breast Cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator-MDACC
Duration: 2/1/2012 - 1/31/2015
Title: Signaling Through the AP-1/Akt Pathway in Anaplastic Large Cell Lymphoma (ALCL) Oncogenesis
Funding Source: Institutional Research Grant (IRG)
Role: Principal Investigator-MDACC
Principal Investigator: Claret
Duration: 3/1/2011 - 2/28/2013
Title: Targeting JAB1- p27Kip1 in Ovarian Cancer
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Principal Investigator-MDACC
Duration: 5/1/2009 - 5/31/2010
Title: Targeting the Stability of p27Kip1 Cell Cycle Inhibitor in Breast Cancer
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Principal Investigator-MDACC
Duration: 10/1/2007 - 9/30/2008
Title: Targeting JAB1 Oncogenic Function
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Duration: 4/1/2007 - 3/31/2013
Title: Role of JAB1 in Breast Tumorigenesis
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Principal Investigator-MDACC
Duration: 5/1/2004 - 4/30/2007
Title: Molecular Mode of Action of JAB1 in the Control of Cell Proliferation
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Duration: 4/1/2002 - 3/31/2008

Last updated: 10/13/2014